A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma
The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Tampa, Florida 33612, United States
Columbus, Ohio 43210, United States
Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ABP, Argentina
CABA, Distrito Federal C1430, Argentina
Ciudad de Buenos Aires, Distrito Federal C1121ABE, Argentina
Changsha Shi, Hunan 410013, China
Lørenskog, Akershus 1478, Norway
Floresti/ Cluj, 407280, Romania